Hello, everyone, and thank you for joining the MedAvail's 2022 Fourth Quarter and Full Year Conference Call. My name is Doug. I will be your operator for today. [Operator Instructions] As a reminder, this conference is being recorded. I now have the pleasure of handing you over to your host, Steve Halper, Managing Director at LifeSci Advisors. Please go ahead.

Thank you all for participating in today's call. Joining me are Mark Doerr, our Chief Executive Officer; and Ramona Seabaugh, Chief Financial Officer. Earlier today, MedAvail Holdings, Inc., referred to as MedAvail or the company released financial results for the fourth quarter and full year ended December 31, 2022. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that the management will make statements during this call, including statements or responses in addressing your questions that include forward-looking statements within the meaning of federal securities laws, which are made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call or in response to your questions that relate to expectations or predictions of future events, results or performance or similar statements are forward-looking statements. All forward-looking statements, including, without limitation, those relating to our operating trends and future financial performance, general market and macroeconomic conditions, including the effect of inflationary pressure, including any impact of adverse developments affecting the financial services industry, such as those based on liquidity constraints or concerns and events, including the outbreak of war in Ukraine or the impact of COVID-19, expense management, expectations for hiring, growth in our organization and reimbursement, market opportunity and expansion and guidance for revenue, gross margins and operating expenses in 2023 are based upon our current estimates and various assumptions. Any forward-looking statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements and do not guarantee future performance. Accordingly, you should not place undue reliance on these statements and should not rely on them in making an investment decision without considering the risks associated with such statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section in our most recent periodic reports including our annual report on Form 10-K, which we plan to file after the market close tomorrow and other filings with the Securities and Exchange Commission. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, March 30, 2023. MedAvail disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events or otherwise. And with that, I will now turn the call over to Mark.

Thank you, Steve, and thanks to all of you for joining us this afternoon for our fourth quarter and full year 2022 financial and operational update. On January 19, MedAvail announced a shift in focus from our SpotRx pharmacy services business to our emerging pharmacy technology business. The underlying technology of MedAvail which includes our MedCenter dispensing kiosks and the associated proprietary MedDispense software remains the core of the value proposition for the company. Through the MedAvail technology business, we offer partners the ability to purchase or lease the MedCenter and to license our software in order to provide point of prescribing, dispensing solutions under their own brand. In the MedAvail pharmacy technology model, partners employ their own pharmacy staff and procure their own inventory. MedAvail pharmacy technology enables providers to dispense medications at the point of care with the following expected appreciable benefits to the patient. More easily initiated medication therapy, reducing prescription abandonment and avoid an additional trip to the pharmacy. Additionally, pharmacies are suffering a current and worsening shortage of both pharmacists and pharmacy technicians, which is resulting in restricted or delayed patient access to medication. The MedCenter is designed to provide patients with enhanced quality and safety through its integrated barcode technology, and convenience with expeditious dispensing times that average 5 to 7 minutes, while offering access to a live pharmacist when needed. There are additional benefits to the clinics that offer the convenience point of prescribing medication dispensing such as improved quality ratings associated with medication compliance and corresponding potential incremental reimbursement revenue. The now discontinued SpotRx pharmacy services experience showed there is a recognized need and demand for this type of solution. What we learned from our pharmacy business will be a material benefit to us going forward. SpotRx grew revenue approximately 100% for…

Thanks, Mark. I will begin with a review of the fourth quarter results before summarizing the full year and touching on our 2023 outlook. For the fourth quarter of 2022, we generated total revenue of $11.4 million, representing growth of 56.9% over the comparable periods in 2021. Revenue from Pharmacy Services was $11.1 million and revenue from Pharmacy Technology was $326,000. Looking at gross profit. Total gross profit for the fourth quarter of 2022 was 1.7%, which the breakdown between divisions being negligible for the Pharmacy Services division and 56% for the Pharmacy Technology division. Total operating expenses for the fourth quarter 2022 were $11 million, down approximately 9.1% from $12 million from the prior year period. Adjusted EBITDA for the fourth quarter was a loss of $8.8 million, representing an improvement as compared to an adjusted EBITDA loss of $10.9 million for the fourth quarter of 2021. Now turning to the full year. For the full year 2022, we generated total revenue of $43.2 million, which surpassed our prior guidance of at least $42 million. This represents a substantial increase as compared to $21.1 million for the full year 2021. Looking at revenue by segment. We generated total revenue of $41.7 million for the Pharmacy Services segment, representing an increase of 107% over $20.2 million for the full year 2021. In Pharmacy Technology, we generated total revenue of $1.4 million for the full year 2022, representing a year-over-year decrease from $1.9 million for the full year 2021. However, our Pharmacy Technology revenue did come in at the high end of our previous guidance range of $1.2 million to $1.4 million. Looking at gross profit. For the full year 2022, we generated gross profit of $2.9 million or 6.7% with a breakdown being 5.3% for Pharmacy Services segment and 49.1%…

Thank you, Ramona. To sum up, I'm excited about the new higher value focus for MedAvail. Going forward, our company consists of the Pharmacy Technology business for which we've identified significant growth opportunities across numerous customer channels. And we have secured funding that can support the business through to profitability. This redirection of the company means that subsequent to the end of 2022, we made the difficult decision to exit our SpotRx pharmacy business and sell certain of its assets to CVS. This allowed us to significantly reduce our operating expenses and our cash burn and focus on a higher return on investment opportunity. I believe we are on the right track to be a leader in the field of pharmacy kiosk dispensing to the benefit of both clinics and patients while creating enduring value for our shareholders. At this point, we'd like to open the call for your questions. Operator?

[Operator Instructions] We have a question from the line of Charles Rhyee with Cowen.

Just trying to understand a little bit here. Obviously, you understand the market opportunity. Anything in -- when we think about the 25 net centers you expect to dispense sort of put in the field this year? I might have missed it. Are these all contracted for already? Or does this assume some level of selling effort that needs to get accomplished as we move through the year?

Charles, thanks for the question, and thanks for joining the call. I would say that on the 25 units we expect to deploy this year, about half of them are contracted for currently.

The other half, has there been -- is this with existing clients where there's some interest expressed? Or is this sort of an estimate of where you think your pipeline currently is?

Yes. We have a much more robust pipeline than that. We have also current customers that expect to expand with us that are just not contracted yet. And so -- we have line of sight that says that the 25, we're highly confident on the 25 at this point and with line of sight to more than that.

Okay. That's helpful. And then the 60% gross margins for the full year, is that something we would expect to see here even in the first quarter with the $600,000 in revenues? Or is that something where -- we're going to average at 60 so that actually our 4Q gross margin, for example, would be above that? Just trying to understand sort of how to think of that ramp in margins through the year as well.

Ramona, do you want to go ahead?

Sure. The gross margin, we would expect to have that throughout the year, starting even in Q1, and that's primarily based on having those units available already without having to expense additional dollars to purchase those since we have those on hand. So we're using a lower depreciated cost.

Okay. And then in terms of the 25 that you're contracted for, like, is there kind of -- should we just -- would you think that there's going to be sort of put in the field sort of ratably across the year? Or are they coming in sort of big kind of -- in kind of bunches, I guess, is the...

Yes, Charles, we would anticipate to see more of them be deployed in the second half of the year than in the first half of the year, the way that they're lining up for deployment at this point.

And then if I recall, Mark, you kind of said before that the way you've done it, you can start to recognize revenue pretty much as soon as it's installed. Is that correct?

Yes. That's how, when it's installed and it can dispense that's when we can start to recognize the revenue, both the onetime revenue from the sale as well as start the monthly recurring revenue stream.

Okay. I know that you talked about where we have enough cash for through '25. Ramona, I don't know if you maybe comment about sort of what the cash burn in the quarter was and what you might think for the course of this year?

We have not yet provided that information, but we do believe that we do -- that we have enough cash for 2025 plus and that by that time, we'll be generating enough revenue to be cash positive. So I think maybe in our next quarterly, we might consider providing more information about our cash burn.

Okay. And the last question for me. What's happening for all the facilities like Oak Street and some of the other clinics in Florida that you had MedCenters in place. What is happening -- have those all been pulled out? And is that what's sitting in inventory? Just understanding what the dynamics for those clinics have been.

Yes, Charles. The vast majority of the MedCenters themselves that were placed in the clinics have been retrieved, probably around 90% have been removed from the clinics and put in the storage for resale. We do think there could still be an opportunity for going back into those clinics with companies such as Oak Street, they have a pharmacy, the CVS deal would close. But we're about 90% done and wrapped up on the [ kiosks ], and that work will be done this month.

Okay. Yes. So I guess that was my question. Like is there any reason why Oak Street couldn't come back and be a technology customer?

They absolutely can. Really the key with the clinics being a partner is usually having a pharmacy partner or running a pharmacy themselves. And that's why Oak Street and the CVS potential acquisition could be a positive sign for going back in because Oak Street was again one of our larger partners and saw the value proposition, both from improved customer satisfaction as well as the impact that we were having on medication adherence in the way that, that drives more reimbursement in those value-based contracts?

Okay. I'm sorry, one last question because you guys in this total addressable market slide, you kind of point out urgent care and primary care. What about retail pharmacy? Because I know years ago that, that was sort of an original idea for the use of MedCenters in your plan and maybe in your sort of sales force. Is there anyone that's targeting the retail pharmacy market as a potential customer base?

Yes, good question. The retail channel, it's large, as you've stated. And what I would say over the near term, we're really optimizing our sales initiatives based on the channels that are more easily penetrated given our proven value proposition that I just talked about as well as with scalable partners that we have. So we have prioritized urgent care and primary care clinics right now because we believe they're more cost-effective and represent a significant opportunity in the near term. It doesn't mean that we're not speaking, not pursuing opportunities that come to us from retail, it's just a matter of prioritization and where we see the pipeline right now is with urgent care, primary care clinics.

I'm showing no further questions at this time. I'd like to hand the call back over to Mr. Doerr for closing remarks.

I just want to say thank you again to everyone that's joining the call or webcast. We look forward to our next quarterly update in May. Have a good night and stay safe.

Ladies and gentlemen, this does conclude today's teleconference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day.